Literature DB >> 1391267

Surfactant replacement therapy and the prevalence of acute retinopathy of prematurity.

T R Tubman1, S J Rankin, H L Halliday, S S Johnston.   

Abstract

To determine if surfactant replacement treatment is associated with an increase in the prevalence of retinopathy of prematurity (ROP) we studied 76 preterm babies who were treated with porcine surfactant (Curosurf) for severe respiratory distress syndrome from 1985 to 1990. Babies were first examined by indirect ophthalmoscopy at the equivalent of 32 weeks post-menstrual age and subsequently at 2-week intervals until discharge from hospital. Findings were documented according to the International Classification of ROP. Sixty-two (82%) babies survived to discharge, 7 survivors were not examined due to transfer elsewhere. Acute ROP developed in 14 (29%) of the 49 babies examined (7 stage I, 4 stage II, 2 stage III, and 1 stage IV); one baby required cryotherapy. No baby of birthweight greater than 1,500 g developed ROP. The prevalence of ROP was similar to that reported for non-surfactant-treated very-low-birthweight babies. We conclude that Curosurf treatment does not increase the risk of acute ROP in surviving very-low-birthweight babies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1391267     DOI: 10.1159/000243845

Source DB:  PubMed          Journal:  Biol Neonate        ISSN: 0006-3126


  3 in total

1.  Surfactant replacement therapy: a new risk factor in developing retinopathy of prematurity?

Authors:  J U Termote; N E Schalij-Delfos; D Wittebol-Post; H A Brouwers; B R Hoogervorst; B P Cats
Journal:  Eur J Pediatr       Date:  1994-02       Impact factor: 3.183

Review 2.  Natural vs synthetic surfactants in neonatal respiratory distress syndrome.

Authors:  H L Halliday
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

3.  Porcine versus bovine surfactant therapy for RDS in preterm neonates: pragmatic meta-analysis and review of physiopathological plausibility of the effects on extra-pulmonary outcomes.

Authors:  Silvia Foligno; Daniele De Luca
Journal:  Respir Res       Date:  2020-01-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.